B+
Bull case
25%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
PNTG
Pennant GroupDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$33.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$25.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+41.0
Score
AI commentary
Deterministic priors lean positive, but the evidence still supports a monitoring-style memo rather than an aggressive long. Evidence quality is only moderate, catalyst density is low, and the forward thesis is still heavily dependent on management executing an integration-heavy 2026 plan already framed in the February 2026 8-K package. [#8-K-2026-02-25]
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystFirst 2026 quarter check against the February guideHigh impact
The key near-term readout is whether the first 2026 quarter supports Pennant's February 25, 2026 guide of $1.1336-$1.1718 billion revenue, $1.26-$1.36 adjusted EPS, and $88.5-$94.1 million adjusted EBITDA. Management said that guide already includes UnitedHealth transition-services costs, reimbursement adjustments, contribution from former UnitedHealth/Amedisys assets, and no unannounced acquisitions, so an early 2026 quarter miss would matter. [#8-K-2026-02-25]
2026-09-30catalystIntegration and local execution across the expanded care footprintHigh impact
The medium-term bull case is continued clean integration of acquired operations while preserving same-store momentum. In the February 25, 2026 earnings release, home health admissions rose 44.1% in 2025, hospice average daily census rose 28.6%, senior-living fourth-quarter occupancy reached 80.6%, and management said 2026 will focus on integrating new operations and instilling operational excellence. The 10-K also shows a scaled footprint of 172 home health and hospice agencies and 63 senior living communities across 16 states, raising both the opportunity and the execution burden. [#8-K-2026-02-25] [#10-K-2026-02-26]
2026-12-31eventAcquisition optionality remains outside formal guidanceHigh impact
Pennant's guidance excludes unannounced acquisitions, leaving event-driven upside if management adds tuck-ins. That option is supported by 2025 operating cash flow of $48.3 million, a $250 million revolving credit facility with maturity in 2029, and a $100 million incremental term loan added in November 2025, although any deal must still clear integration capacity and reimbursement risk. [#8-K-2026-02-25] [#10-K-2026-02-26]
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology